Novartis says 330 jobs hit as it closes MorphoSys sites

Novartis plans to close MorphoSys sites in Germany and the US by 2025, impacting 330 jobs, in line with its R&D strategy assessment after acquiring the company.

Sandoz settles US antitrust case for $275m

Sandoz settled a US Generic Drug Antitrust Class Action for $275 million, with additional provisions for outstanding claims, marking a significant step in resolving litigation.

Unsupported price hikes added $815 million to US drug spending in 2023

A report reveals five drugs accounted for $815 million in U.S. spending increases in 2023 without clinical evidence, highlighting ongoing pricing issues in the pharmaceutical industry.

Nvidia, Palo Alto, Baidu fall premarket; Snowflake, Deere rise

Novartis upgrades sales forecast

Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper

Novartis anticipates at least 5% annual sales growth until 2028 despite patent expirations, supported by new medications and potential acquisitions, maintaining a stable profit margin.

Novartis lifts annual outlook for third time after sales and profits top estimates

Novartis raises annual earnings guidance due to rising sales and profits, while also exploring an obesity drug amidst strong demand for existing treatments like Cosentyx.

STOXX 600 inches higher led by banks; mixed earnings cap gains

European markets rose slightly as bank stocks gained from HSBC's earnings, though other poor reports tempered overall gains amid cautious sentiment ahead of the U.S. election.

European stocks lower as investors digest earnings; Germany needs reforms - IMF

Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs

Novartis agrees to pay Monte Rosa $150 million for drug development rights, significantly enhancing its pipeline while preparing for patent loss on key medications.